Get the Stockscreener App
78.72
0.24%
-0.2178
Ani Pharmaceuticals Inc stock is traded at $78.72, with a volume of 309.30K.
It is down -0.24% in the last 24 hours and down -4.10% over the past month.
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid-dose products. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended-release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. The company operates in two segments which include Rare Diseases and Brands, Generics, and Others. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.
See More
Previous Close:
$78.94
Open:
$79.1
24h Volume:
309.30K
Relative Volume:
0.81
Market Cap:
$1.77B
Revenue:
$747.40M
Net Income/Loss:
$-12.60M
P/E Ratio:
-102.41
EPS:
-0.7687
Net Cash Flow:
$105.18M
1W Performance:
-4.44%
1M Performance:
-4.10%
6M Performance:
+20.75%
1Y Performance:
+42.05%
1-Day Range:
$77.78
$80.28
1-Week Range:
$77.78
$82.53
52-Week Range:
$52.73
$99.50
Ani Pharmaceuticals Inc Stock (ANIP) Company Profile
Name
Ani Pharmaceuticals Inc
Sector
Phone
(218) 634-3500
Address
210 MAIN STREET WEST, BAUDETTE, MN
Compare ANIP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ANIP
Ani Pharmaceuticals Inc
|
78.75 | 1.77B | 747.40M | -12.60M | 105.18M | -0.7687 |
|
ZTS
Zoetis Inc
|
125.41 | 55.45B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.62 | 49.25B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
10.02 | 45.02B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
30.64 | 35.81B | 16.88B | 666.71M | 251.19M | 0.6132 |
|
UTHR
United Therapeutics Corp
|
491.72 | 20.98B | 3.08B | 1.24B | 1.07B | 25.61 |
Ani Pharmaceuticals Inc Stock (ANIP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-10-25 | Initiated | H.C. Wainwright | Buy |
| Mar-14-25 | Initiated | Jefferies | Buy |
| Mar-12-25 | Initiated | JP Morgan | Overweight |
| Dec-11-24 | Initiated | Leerink Partners | Outperform |
| Oct-11-24 | Initiated | Piper Sandler | Overweight |
| Mar-15-24 | Initiated | CapitalOne | Overweight |
| Aug-22-23 | Reiterated | H.C. Wainwright | Buy |
| Mar-01-23 | Initiated | Guggenheim | Buy |
| Sep-07-22 | Initiated | H.C. Wainwright | Buy |
| Nov-02-21 | Initiated | Truist | Buy |
| May-07-20 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Sep-12-19 | Initiated | Guggenheim | Buy |
| May-10-19 | Downgrade | Raymond James | Strong Buy → Outperform |
| Oct-16-17 | Reiterated | Canaccord Genuity | Buy |
| Jul-31-17 | Initiated | Canaccord Genuity | Buy |
| Feb-22-17 | Downgrade | ROTH Capital | Buy → Neutral |
| Jun-23-16 | Initiated | Raymond James | Strong Buy |
| May-24-16 | Downgrade | Standpoint Research | Buy → Hold |
| Nov-13-15 | Initiated | Standpoint Research | Buy |
| Sep-28-15 | Upgrade | ROTH Capital | Neutral → Buy |
| Aug-05-15 | Reiterated | Oppenheimer | Outperform |
| Aug-04-15 | Reiterated | ROTH Capital | Neutral |
| Jul-31-15 | Reiterated | Oppenheimer | Outperform |
| Jul-15-15 | Reiterated | ROTH Capital | Neutral |
| Jun-23-15 | Reiterated | Oppenheimer | Outperform |
| May-18-15 | Reiterated | ROTH Capital | Neutral |
| May-06-15 | Reiterated | Oppenheimer | Outperform |
| Apr-10-15 | Downgrade | ROTH Capital | Buy → Neutral |
| Feb-26-15 | Reiterated | ROTH Capital | Buy |
| Feb-18-15 | Reiterated | Oppenheimer | Outperform |
View All
Ani Pharmaceuticals Inc Stock (ANIP) Latest News
Is ANI Pharmaceuticals (ANIP) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Revenue per share of ANI Pharmaceuticals, Inc. – MUN:BSFA - TradingView — Track All Markets
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Q4 2024 Earnings Call Transcript - MSN
ANI Stock Is Up 49% This Past Year, Revenue Is Surging, and One Fund Still Walked Away - The Globe and Mail
ANI Stock Is Up 49% This Past Year, Revenue Is Surging, and One Fund Still Walked Away - The Motley Fool
ANI Pharmaceuticals, Inc. $ANIP Shares Sold by Rice Hall James & Associates LLC - MarketBeat
Assessing ANI Pharmaceuticals (ANIP) Valuation After a Strong Yearly Share Price Rally - Yahoo Finance
ANI Pharma stock pullback tied to Cortrophin guidance uncertainty - Investing.com
ANI Pharmaceuticals, Inc. $ANIP Shares Purchased by Assenagon Asset Management S.A. - MarketBeat
ANI Pharmaceuticals (NASDAQ:ANIP) Trading Down 3.6% on Insider Selling - MarketBeat
ANI Pharmaceuticals to Report Q1 Earnings: Is a Beat in the Cards? - MSN
Will ANI Pharmaceuticals Inc. stock attract ESG investorsMarket Trend Summary & AI Powered Market Entry Ideas - Улправда
ANI Pharmaceuticals (NASDAQ:ANIP) SVP Sells $133,652.80 in Stock - MarketBeat
ANI Pharmaceuticals Executive Sells Shares - TradingView — Track All Markets
VP Davis Sells 1,622 ($133.7K) Of ANI Pharmaceuticals Inc [ANIP] - TradingView — Track All Markets
How ANI Pharmaceuticals Inc. stock reacts to global recession fearsMarket Growth Review & Reliable Price Breakout Signals - DonanımHaber
Squarepoint Ops LLC Takes $2.14 Million Position in ANI Pharmaceuticals, Inc. $ANIP - MarketBeat
Can ANI Pharmaceuticals Inc. stock rebound after recent weaknessQuarterly Trade Review & Daily Oversold Bounce Ideas - DonanımHaber
Is ANI Pharmaceuticals Inc. stock trading at a premium valuationWeekly Gains Summary & Weekly Watchlist for Hot Stocks - Улправда
Can ANI Pharmaceuticals Inc. stock deliver consistent earnings growthJuly 2025 Recap & Safe Capital Growth Tips - Улправда
ANI Pharmaceuticals (ANIP): Assessing Valuation After Recent Share Price Momentum - Sahm
Zacks Industry Outlook Arcutis, Amicus and ANI - The Globe and Mail
Why ANI Pharmaceuticals Inc. stock attracts high net worth investorsJuly 2025 Chart Watch & Fast Gaining Stock Reports - Улправда
FDA Grants Fast Track Designation to ADAG's Colorectal Cancer Drug - Finviz
Is ANI Pharmaceuticals Stock Price Justified After 47% 2025 Rally? - Yahoo Finance
How Investors May Respond To ANI Pharmaceuticals (ANIP) Creating a Retina-Focused FutureVision Advisory Council - Yahoo Finance
Are Medical Stocks Lagging ANI Pharmaceuticals (ANIP) This Year? - Yahoo Finance
Ranger Investment Management L.P. Reduces Stock Holdings in ANI Pharmaceuticals, Inc. $ANIP - MarketBeat
Implied volatility surging for ANI Pharmaceuticals stock options - MSN
ANI Pharmaceuticals (NASDAQ:ANIP) VP Sells $32,928.00 in Stock - MarketBeat
ANI Pharmaceuticals Senior VP Meredith Cook Sells 400 Shares - TradingView — Track All Markets
ANI Pharmaceuticals (ANIP) officer Meredith Cook sells 400 shares via 10b5-1 plan - Stock Titan
ANI Pharmaceuticals price target raised to $115 from $114 at Guggenheim - MSN
ANI Pharmaceuticals (ANIP): Assessing Valuation After a Strong Year and Recent Share Price Pullback - Sahm
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Receives Consensus Rating of "Buy" from Analysts - MarketBeat
ANI Pharmaceuticals to Report Q3 Earnings: Is a Beat in the Cards? - MSN
Implied Volatility Surging for ANI Pharmaceuticals Stock Options - Nasdaq
ANI Pharmaceuticals Completes Mandatory Conversion of Preferred Shares - MSN
ANI Pharmaceuticals Director Sold $146K In Company Stock - Benzinga
ANI Pharmaceuticals (NASDAQ:ANIP) Director Sells $146,070.00 in Stock - MarketBeat
ANI Pharmaceuticals Director Sells 1,800 Shares - TradingView — Track All Markets
ANI Pharmaceuticals (NASDAQ:ANIP) Coverage Initiated by Analysts at Barclays - MarketBeat
Barclays Initiates ANI Pharmaceuticals at Overweight With $100 Price Target - marketscreener.com
ANI Pharmaceuticals chairman Patrick Walsh to retire, Thomas Haughey to succeed - MSN
ANI Pharmaceuticals (ANIP): Has the Recent Share Price Pullback Created a Valuation Opportunity? - Yahoo Finance
ANI Pharmaceuticals, Inc. $ANIP Shares Sold by JPMorgan Chase & Co. - MarketBeat
Kennedy Capital Management LLC Reduces Stake in ANI Pharmaceuticals, Inc. $ANIP - MarketBeat
The Bull Case For ANI Pharmaceuticals (ANIP) Could Change Following Governance Shake-Up And FutureVision Launch – Learn Why - Sahm
Is ANI Pharmaceuticals Inc. (BSFA) stock a buy for dividend portfoliosPortfolio Performance Report & Low Drawdown Investment Strategies - Newser
ANI Pharmaceuticals (ANIP): Valuation Check After Governance Shake-Up and New Rare Disease Strategy Moves - Sahm
Sio Capital Management LLC Buys 25,625 Shares of ANI Pharmaceuticals, Inc. $ANIP - MarketBeat
Ani Pharmaceuticals Inc Stock (ANIP) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.43%
2.14%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):